Cargando…
Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy
DPX is a unique T cell activating formulation that generates robust immune responses (both clinically and preclinically) which can be tailored to various cancers via the use of tumor-specific antigens and adjuvants. While DPX-based immunotherapies may act complementary with checkpoint inhibitors, co...
Autores principales: | Tremblay, Marie-Laurence, O’Brien-Moran, Zoe, Rioux, James A., Nuschke, Andrea, Davis, Christa, Kast, W. Martin, Weir, Genevieve, Stanford, Marianne, Brewer, Kimberly D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714509/ https://www.ncbi.nlm.nih.gov/pubmed/33299663 http://dx.doi.org/10.1080/2162402X.2020.1851539 |
Ejemplares similares
-
Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillusanthracis spore inhalation challenge
por: Weir, Genevieve M., et al.
Publicado: (2019) -
Therapeutic vaccines and cancer: focus on DPX-0907
por: Karkada, Mohan, et al.
Publicado: (2014) -
Using lymph node swelling as a potential biomarker for successful vaccination
por: Brewer, Kimberly D., et al.
Publicado: (2016) -
Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy
por: Karkada, Mohan, et al.
Publicado: (2013) -
CX, DPX and PRIDE: WWW servers for the analysis and comparison of protein 3D structures
por: Vlahoviček, Kristian, et al.
Publicado: (2005)